deferoxamine has been researched along with Cardiac Hypertrophy in 10 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effects of the iron chelator deferoxamine on the functional and structural manifestations of iron-induced cardiac dysfunction, we measured cardiac power, left ventricular systolic, and diastolic function as (dP/dt)max and (dP/dt)min, respectively, and left ventricular and septal wall thickness in isolated heart preparations derived from the Mongolian gerbil model of iron overload." | 7.72 | Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. ( Brittenham, GM; Brown, AM; Dong, WQ; Kuryshev, YA; Levy, MN; Obejero-Paz, CA; Yang, T, 2003) |
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 5.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| "To evaluate the effects of the iron chelator deferoxamine on the functional and structural manifestations of iron-induced cardiac dysfunction, we measured cardiac power, left ventricular systolic, and diastolic function as (dP/dt)max and (dP/dt)min, respectively, and left ventricular and septal wall thickness in isolated heart preparations derived from the Mongolian gerbil model of iron overload." | 3.72 | Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. ( Brittenham, GM; Brown, AM; Dong, WQ; Kuryshev, YA; Levy, MN; Obejero-Paz, CA; Yang, T, 2003) |
| "Deferoxamine treated control myocytes responded similarly." | 1.36 | Hypoxia inducible factor-1 improves the negative functional effects of natriuretic peptide and nitric oxide signaling in hypertrophic cardiac myocytes. ( Scholz, PM; Tan, T; Weiss, HR, 2010) |
| "We enrolled nine patients with thalassemia major complicated by some degree of myocardial dysfunction." | 1.33 | Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. ( Chang, JS; Huang, YC; Peng, CT; Wu, KH, 2006) |
| "Deferoxamine (50 mumol/kg) was given to one group with the hypertrophied hearts during the first 10 minutes of reperfusion." | 1.28 | Deferoxamine fails to improve postischemic cardiac function in hypertrophied hearts. ( del Nido, PJ; Feinberg, H; Jimenez, E; Levitsky, S; Nakamura, H; Sarin, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choy, MK | 1 |
| Movassagh, M | 1 |
| Bennett, MR | 1 |
| Foo, RS | 1 |
| Tan, T | 1 |
| Scholz, PM | 1 |
| Weiss, HR | 1 |
| Yang, T | 1 |
| Brittenham, GM | 1 |
| Dong, WQ | 1 |
| Levy, MN | 1 |
| Obejero-Paz, CA | 1 |
| Kuryshev, YA | 1 |
| Brown, AM | 1 |
| Huang, YC | 1 |
| Chang, JS | 1 |
| Wu, KH | 1 |
| Peng, CT | 1 |
| Hehlmann, R | 1 |
| Schmitz, H | 1 |
| Krüger, K | 1 |
| Engle, MA | 1 |
| Ehlers, KH | 1 |
| O'Loughlin, JE | 1 |
| Giardina, PJ | 1 |
| Hilgartner, MW | 1 |
| Fields, M | 1 |
| Lewis, CG | 1 |
| Lure, M | 1 |
| Nakamura, H | 1 |
| del Nido, PJ | 1 |
| Jimenez, E | 1 |
| Sarin, M | 1 |
| Levitsky, S | 1 |
| Feinberg, H | 1 |
| Silvestroni, E | 1 |
| Bianco, I | 1 |
| Masi, M | 1 |
| Seshadri, R | 1 |
| Colebatch, JH | 1 |
| Gordon, P | 1 |
| Ekert, H | 1 |
10 other studies available for deferoxamine and Cardiac Hypertrophy
| Article | Year |
|---|---|
PKB/Akt activation inhibits p53-mediated HIF1A degradation that is independent of MDM2.
Topics: Animals; Cardiomegaly; Cell Line; Cell Size; Chromones; Deferoxamine; Disease Models, Animal; Fibrob | 2010 |
Hypoxia inducible factor-1 improves the negative functional effects of natriuretic peptide and nitric oxide signaling in hypertrophic cardiac myocytes.
Topics: Animals; Carbazoles; Cardiomegaly; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Deferoxamine; D | 2010 |
Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy.
Topics: Animals; Cardiomegaly; Cardiomyopathies; Deferoxamine; Female; Gerbillinae; Heart Failure; Iron; Iro | 2003 |
Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiomegaly; Cardiomyopathies; Chelation Therapy; Cohort Studi | 2006 |
Iron overload in cardiac valvular disease and pure red cell aplasia: treatment with desferrioxamine.
Topics: Anemia, Aplastic; Atrial Fibrillation; Cardiomegaly; Deferoxamine; Female; Hemosiderosis; Humans; Ir | 1984 |
Beta thalassemia and heart disease: three decades of gradual progress.
Topics: Blood Transfusion; Cardiomegaly; Child; Deferoxamine; Erythrocyte Transfusion; Heart Diseases; Human | 1985 |
The influence of dietary carbohydrate and deferoxamine on developing copper deficiency of rats.
Topics: Animals; Cardiomegaly; Copper; Deferoxamine; Dietary Carbohydrates; Hematocrit; Male; Rats; Rats, In | 1992 |
Deferoxamine fails to improve postischemic cardiac function in hypertrophied hearts.
Topics: Animals; Cardiomegaly; Deferoxamine; Free Radical Scavengers; Myocardial Reperfusion; Myocardial Rep | 1990 |
[Research on the effect of desferrioxamine B in patients with Cooley's disease].
Topics: Adolescent; Adult; Cardiomegaly; Child; Child, Preschool; Deferoxamine; Female; Hepatomegaly; Humans | 1967 |
Long-term administration of desferrioxamine in thalassaemia major.
Topics: Adolescent; Adult; Aspartate Aminotransferases; Bilirubin; Blood Protein Electrophoresis; Blood Tran | 1974 |